Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343294 | 0.90 | MARS1 (0.36) | HPGDMAPK1MARS1MEN1KMT2A | |
| SCHEMBL1345418 | 0.89 | HPGD (0.35) | HPGDMARS1MEN1KMT2ATDP1 | |
| SCHEMBL1345236 | 0.87 | NOD1 (0.39) | MARS1NOD1ALDH1A1 | |
| SCHEMBL1345051 | 0.84 | HPGD (0.32) | HPGDMAPK1MARS1MEN1KMT2A | |
| SCHEMBL1345150 | 0.83 | DDAH1 (0.42) | HPGDTDP1ALDH1A1DDAH1 | |
| SCHEMBL1344938 | 0.79 | SLC1A3 (0.47) | HPGDMAPK1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1343488 | 0.76 | DDAH1 (0.43) | HPGDMARS1CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4093663 | 0.73 | ALDH1A1 (0.38) | HPGDMEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL1345589 | 0.72 | DPP7 (0.42) | HPGDTDP1ALDH1A1DDAH1 | |
| SCHEMBL9330200 | 0.71 | DPP7 (0.42) | MEN1KMT2ANOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828109-B1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL BUSINESS PLC (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8063104-B2 | Guanidine derivatives as inhibitors of DDAH | UCL BUSINESS PLC (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | UCL Biomedica PLC c/o Finance Division University College of London (GB) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069331-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF DDAH | DDAH1, DOHH, IMPDH1 | HPGD 148/4885MAPK1 1979/4885MARS1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.